Korean J Gastroenterol.  2020 Sep;76(3):174-176. 10.4166/kjg.2020.76.3.174.

Treatment Outcome of Matched Therapy after Molecular Profiling in Patients with Advanced Pancreatic Cancer

• Cho IR

• KMID: 2506676
• DOI: http://doi.org/10.4166/kjg.2020.76.3.174

Reference

1. Cho IR, Kang H, Jo JH, et al. 2020; FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study. World J Gastrointest Oncol. 12:182–194. DOI: 10.4251/wjgo.v12.i2.182. PMID: 32104549. PMCID: PMC7031147.

2. Pishvaian MJ, Bender RJ, Halverson D, et al. 2018; Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin Cancer Res. 24:5018–5027. DOI: 10.1158/1078-0432.CCR-18-0531. PMID: 29954777.

3. Tempero MA. 2019; NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 17:603–605. DOI: 10.6004/jnccn.2019.0003. PMID: 30659122.

4. Aguirre AJ, Nowak JA, Camarda ND, et al. 2018; Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov. 8:1096–1111. DOI: 10.1158/2159-8290.CD-18-0275. PMID: 29903880. PMCID: PMC6192263.

5. Lowery MA, Jordan EJ, Basturk O, et al. 2017; Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res. 23:6094–6100. DOI: 10.1158/1078-0432.CCR-17-0899. PMID: 28754816.

6. Le DT, Uram JN, Wang H, et al. 2015; PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372:2509–2520. DOI: 10.1056/NEJMoa1500596. PMID: 26028255. PMCID: PMC4481136.

7. Drilon A, Laetsch TW, Kummar S, et al. 2018; Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 378:731–739. DOI: 10.1056/NEJMoa1714448. PMID: 29466156. PMCID: PMC5857389.

8. Golan T, Hammel P, Reni M, et al. 2019; Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 381:317–327. DOI: 10.1056/NEJMoa1903387. PMID: 31157963. PMCID: PMC6810605.

9. Pishvaian MJ, Wang H, He AR, et al. 2020; Jul. 15. A Phase I/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clin Cancer Res. [Epub ahead of print]. DOI: 10.1158/1078-0432.CCR-20-1301. PMID: 32669374.

10. Shroff RT, Hendifar A, McWilliams RR, et al. 2018; Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol. 2018:DOI: 10.1200/PO.17.00316. PMID: 30051098. PMCID: PMC6057747.